Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Airs Medical, Avance Clinical, Bioptimus, Biosig, Elephas, Lazurite, Lifecore, Medtronic, Owkin, Paragoncare, Ryght.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Diacarta, Wellvii, Werfen, X-trodes.
Researchers from the Academic Medical Center (AMC) University of Amsterdam are seeking protection for their invention of a total artificial heart which is compact, durable and mimics the natural movement of human tissue.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Angiodynamics, Autonomix, Intelligent Bio, Precisionlife, Spectrum Vascular, T2 Biosystems.
Despite a slowdown in the fourth quarter (Q4), med-tech deals concluded the year with the highest deal-value total in BioWorld MedTech’s records. In 2023, a total of $10.63 billion was raised from deals, a 33% increase over the $7.99 billion deal total in 2022. Meanwhile, annual M&A value dropped 58%, from $153.09 billion in 2022 to $64.8 billion in 2023.
The U.S. FDA reported Feb. 15 that Philips USA, a subsidiary of Amsterdam-based Royal Philips NV, recalled three models of the Brightview line of single photon emission CT (SPECT) systems due to an incident in which the system detector fell.
Shionogi & Co. Ltd. is partnering with Fronteo Inc. to develop artificial intelligence (AI)-based diagnostic tools to diagnose mental and neurological disorders more accurately.
Wandercraft SAS broadened its U.S. FDA clearance for the Atalante X to include rehabilitation in individuals with spinal cord injuries at levels T5 to L5. The self-balancing exoskeleton was already given the greenlight by the FDA for use in stroke rehabilitation in December 2022. “We are thrilled to have two FDA clearances, first for stroke and now spinal cord injury, in less than a year,” CEO Matthieu Masselin, told BioWorld.
RSS
